The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Checkpoint inhibitor-based immunotherapies that target cytotoxic T lymphocyte antigen 4 (CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success in the treatment of different cancer types. Yet, only a subset of patients derive clinical benefit. It is thus critical to understand the determinants driving response, resista...
Alternative Titles
Full title
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6705396
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6705396
Other Identifiers
ISSN
1474-175X
E-ISSN
1474-1768
DOI
10.1038/s41568-019-0116-x
